Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

tiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... YORK , July 29, 2015  Therapath ... testing, announces increased partnerships with VA and Military ... Epidermal Nerve Fiber Density (ENFD) and Sweat Gland ... small fiber neuropathy ( https://therapath.com/skin ). ... Nerve Fiber Density (ENFD) on punch skin biopsy ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
(Date:7/29/2015)... ... July 29, 2015 , ... Rainbow Scientific, Inc. (RSI), a ... availability of BI’s line of human mesenchymal stem cell (hMSC) differentiation media, ... offer a complete system for multipotency evaluation of hMSCs and reliable induction of ...
(Date:7/28/2015)... ... ... new Xsample 530 sample changer for vials can be used with Anton Paar ... less than 12,000 mPas (internal air) up to 36,000 (external air) – and can process ... about Xsample 530 is its removable magazine, which is easily lifted off its hub and ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... Company Increases Revenue and Earnings Guidance for 2008 Based on ... Continuing Adoption of HeartMate ... THOR ), a world leader in device-based mechanical,circulatory support therapies ... for the third quarter of 2008 increased 44 percent,over revenues ...
... BUCHAREST, October 30 In a joint press ... first customer,oriented cellular e-health service., "Health is ... which is why,Orange and Medic4all are launching together ... Fixed Data Services Development,Manager for Orange Romania., ...
... of PulmoSmartChip - A ... Lung Disease, FREMONT, Calif., Oct. 30 WaferGen ... state-of-the-art,gene expression, genotyping, cell biology and stem cell research ... has awarded a,team of researchers at University of Pittsburgh ...
Cached Biology Technology:Thoratec Reports 44 Percent Increase in Third Quarter Revenues 2Thoratec Reports 44 Percent Increase in Third Quarter Revenues 3Thoratec Reports 44 Percent Increase in Third Quarter Revenues 4Thoratec Reports 44 Percent Increase in Third Quarter Revenues 5Thoratec Reports 44 Percent Increase in Third Quarter Revenues 6Thoratec Reports 44 Percent Increase in Third Quarter Revenues 7Thoratec Reports 44 Percent Increase in Third Quarter Revenues 8Thoratec Reports 44 Percent Increase in Third Quarter Revenues 9Thoratec Reports 44 Percent Increase in Third Quarter Revenues 10Thoratec Reports 44 Percent Increase in Third Quarter Revenues 11Thoratec Reports 44 Percent Increase in Third Quarter Revenues 12Thoratec Reports 44 Percent Increase in Third Quarter Revenues 13Thoratec Reports 44 Percent Increase in Third Quarter Revenues 14Orange and Medic4all Launched the World's First Cellular Tele-Health Service 2NIH Awards Approximately $3M Grant for Research Involving WaferGen's SmartChip(TM) Real-Time PCR System at the University of Pittsburgh 2NIH Awards Approximately $3M Grant for Research Involving WaferGen's SmartChip(TM) Real-Time PCR System at the University of Pittsburgh 3NIH Awards Approximately $3M Grant for Research Involving WaferGen's SmartChip(TM) Real-Time PCR System at the University of Pittsburgh 4NIH Awards Approximately $3M Grant for Research Involving WaferGen's SmartChip(TM) Real-Time PCR System at the University of Pittsburgh 5NIH Awards Approximately $3M Grant for Research Involving WaferGen's SmartChip(TM) Real-Time PCR System at the University of Pittsburgh 6
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... other types of "biomass" serve as an essential source ... content has raised flags among environmentalists and researchers. Scientists ... biomass, processed pellets burned under realistic conditions in China ... The report was published in the ACS journal ...
... development and millions of dollars are typically the costs, ... short cuts to a treatment are welcome. Researchers at ... discovered such a potential short cut. "Our new ... a treatment faster and cheaper than usual in the ...
... direct current potential difference between the site of spinal ... is a significant indicator of the severity of spinal ... current, can be modulated by direct current field stimulation; ... hard to define. Dr. Guanghao Zhang and colleagues from ...
Cached Biology News:Genetic aberration paves the way for new treatment of cancer disease 2
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
Biology Products: